The present application overcomes the shortcomings of the prior art as described herein. However, formulating an AV particle that can efficiently and safely deliver both therapeutic genes and proteins into the target cell to remodel human genome is still a major challenge.
Background of the Inventionĭesigning “artificial viruses” (AVs) programmed with biomolecules that can enter human cells and carry out precise molecular repairs will have broad applications to medicine.
The present disclosure relates to generally to a human genome remodeling components, compositions, mechanisms and methods thereof. 7, 2021, is 51,445 bytes in size and is hereby incorporated by reference in its entirety. This Sequence Listing is named 109007-23787US01_sequence listing.TXT was created on Jun. The present application includes a Sequence Listing which has been submitted electronically in an ASCII text format. The government has certain rights in the invention. MCB-0923873 awarded by The National Science Foundation (NSF). AI111538 and AI081726 awarded by The National Institutes of Health (NIH) and Grant No. This invention was made with the United States government support under Grant Nos. The entire contents and disclosures of these patent applications are incorporated herein by reference in their entirety. 63/058,012, entitled “Design of Bacteriophage-based Artificial Viruses for Human Genome Remodeling,” filed Jul. This application also claims benefit of priority of U.S. 19, 2019, entitled “A Prokaryotic-Eukaryotic Hybrid Viral Vector for Delivery of Large Cargos of Genes and Proteins into Human Cells”. 26, 2021, which claims benefit of priority of U.S. 16/990,289, entitled “Prokaryotic-Eukaryotic Hybrid Viral Vector for Delivery of Large Cargos of Genes and Proteins into Human Cells,” filed Aug. This application is a continuation in part of claims benefit of priority of U.S.